The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The present disclosure concerns a method for preparing an extracorporeal blood circuit for its use in a blood treatment of a patient, which treatment is carried out using a blood treatment apparatus and using a blood treatment device, which comprises a blood chamber and a dialysate chamber partitioned off therefrom by a membrane, The method comprising: filling the extracorporeal blood circuit using a priming solution, wherein the priming solution comprises citrate, or filling of the extracorporeal blood circuit using a priming solution and using a citrate solution. The invention further comprises devices suitable for carrying out the method.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

The invention relates to an apparatus for extracorporeal removal of protein-bound toxins from blood plasma comprising a first line device, a second line device, a third line device and a fourth line device, a dialyzer or hemofilter arranged between the first line device and the second line device and/or an adsorber, means for generating a field, at least partially surrounding the first line device and/or the dialyzer or hemofilter and/or the adsorber, a controllable fluid conveyance device arranged in the first line device and/or the second line device, and at least one controllable body fluid conveyance unit arranged in the third line device and/or the fourth line device, a filter, wherein the permeate side of the filter is connected to the first line device and the second line device, and the side of the filter to be dialyzed is connected at its inlet to the third line device, which can be connected to a patient and is connected at its outlet to the fourth line device which can be connected to the patient, wherein a controllable flow of fluid through the line devices and the dialyzer or hemofilter and/or the adsorber can be generated by means of the fluid conveyance devices.

Described herein are systems and methods for creating a transport tube comprising a plurality of passages configured to deliver an composition from a source into the human subcutaneous space.

The present disclosure is directed to methods of removing proteins, including cytokines, from blood and blood products, the methods comprising contacting the blood or blood product with a form of carbon having high graphitic contents and slit-shaped mesopores and macropores, the pore size dimensions chosen to be comparable to the size of the proteins, wherein the contacting results in the removal of high levels of the protein from the blood or blood product in minutes or hours.

Catheters, catheter ports, connectors, and related methods are disclosed herein, e.g., for drug delivery to a subject. The catheters and catheter ports can include various features to facilitate dosing protocols that require multiple injections, and/or for reducing or eliminating damage that may occur to the catheter, port, or patient tissue as a result of multiple injections.